http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
오늘 본 자료
( Gi-june Min ),( Young-woo Jeon ),( Sung-soo Park ),( Silvia Park ),( Seung-hawn Shin ),( Seung-ah Yahng ),( Jae-ho Yoon ),( Sung-eun Lee ),( Byung-sik Cho ),( Ki-seong Eom ),( Yoo-jin Kim ),( Seok L 대한내과학회 2021 The Korean Journal of Internal Medicine Vol.36 No.2
Background/Aims: Idiopathic multicentric Castleman disease (iMCD) comprises approximately 30% of all cases of Castleman disease. It is characterized by constitutional symptoms, enlarged lymph nodes at multiple anatomical sites, and laboratory test abnormalities, which are primarily related to the overproduction of interleukin 6 (IL-6). Siltuximab is a human-mouse chimeric immunoglobulin G1κ monoclonal antibody against human IL-6. In view of the limited treatment options for iMCD, this study aimed to evaluate the efficacy and safety of siltuximab in the management of this condition. Methods: In this real-world retrospective study, we administered siltuximab to 15 patients with iMCD who previously received conventional chemotherapy and/or steroid pulse therapy. The median time to a durable symptomatic response was 22 days (range, 17 to 56). The serum hemoglobin and albumin levels and erythrocyte sedimentation rates significantly normalized after the first 3 months of siltuximab treatment. Lymph node involution, assessed using imaging, was relatively gradual, demonstrating a complete or partial response at 6 months. Results: On an average, the improvements in clinical, laboratory, and radiologic parameters of iMCD in responders were observed after one, three, and eight cycles of siltuximab treatment, respectively. Siltuximab demonstrated a favorable safety profile, and prolonged treatment was well-tolerated. Conclusions: Despite the small sample size of the present study, the results are encouraging and demonstrate the potential of siltuximab as the first-line treatment of iMCD. Further large multicenter studies are needed to evaluate the clinical outcomes and adverse events associated with siltuximab.
A Case of Multicentric Castleman's Disease Presenting with Follicular Bronchiolitis
HwangBo, Yup,Cha, Seung-Ick,Lee, Yong Hoon,Lee, So Yeon,Seo, Hyewon,Oh, Serim,Kim, Minjung,Choi, Sun Ha,Park, Tae In,Shin, Kyung-Min The Korean Academy of Tuberculosis and Respiratory 2013 Tuberculosis and Respiratory Diseases Vol.74 No.1
Multicentric Castleman's disease (CD) is a rare atypical lymphoproliferative disorder, which is characterized by various systemic manifestations. Some patients with multicentric CD may have concomitant lung parenchymal lesions, for which lymphoid interstitial pneumonia (LIP) is known to be the most common pathologic finding. Follicular bronchiolitis and LIP are considered to be on the same spectrum of the disease. We describe a case of multicentric CD with pulmonary involvement, which was pathologically proven as follicular bronchiolitis.
A Case of Multicentric Castleman's Disease Presenting with Follicular Bronchiolitis
황보엽,차승익,이용훈,이소연,서혜원,오세림,김민정,최선하,박태인,신경민 대한결핵및호흡기학회 2013 Tuberculosis and Respiratory Diseases Vol.74 No.1
Multicentric Castleman's disease (CD) is a rare atypical lymphoproliferative disorder, which is characterized by various systemic manifestations. Some patients with multicentric CD may have concomitant lung parenchymal lesions, for which lymphoid interstitial pneumonia (LIP) is known to be the most common pathologic finding. Follicular bronchiolitis and LIP are considered to be on the same spectrum of the disease. We describe a case of multicentric CD with pulmonary involvement, which was pathologically proven as follicular bronchiolitis.
A Case of Multicentric Castleman's Disease Presenting with Follicular Bronchiolitis
Yup Hwang Bo,Seung Ick Cha,Yong Hoon Lee,So Yeon Lee,Hye Won Seo,Se Rim Oh,Min Jung Kim,Sun Ha Choi,Tae In Park,Kyung Min Shin 대한결핵 및 호흡기학회 2013 Tuberculosis and Respiratory Diseases Vol.74 No.1
Multicentric Castleman's disease (CD) is a rare atypical lymphoproliferative disorder, which is characterized by various systemic manifestations. Some patients with multicentric CD may have concomitant lung parenchymal lesions, for which lymphoid interstitial pneumonia (LIP) is known to be the most common pathologic finding. Follicular bronchiolitis and LIP are considered to be on the same spectrum of the disease. We describe a case of multicentric CD with pulmonary involvement, which was pathologically proven as follicular bronchiolitis.